These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2015840)

  • 1. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid.
    May TW; Rambeck B; Nothbaum N
    Eur Neurol; 1991; 31(1):57-60. PubMed ID: 2015840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication.
    May T; Rambeck B
    Ther Drug Monit; 1990 Mar; 12(2):124-8. PubMed ID: 2107607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparison of two prediction methods.
    Kerrick JM; Wolff DL; Graves NM
    Ann Pharmacother; 1995 May; 29(5):470-4. PubMed ID: 7655129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid.
    Haidukewych D; Rodin EA; Zielinski JJ
    Ther Drug Monit; 1989; 11(2):134-9. PubMed ID: 2497562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid-phenytoin interaction.
    Friel PN; Leal KW; Wilensky AJ
    Ther Drug Monit; 1979; 1(2):243-8. PubMed ID: 122160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children.
    Ueshima S; Aiba T; Makita T; Nishihara S; Kitamura Y; Kurosaki Y; Kawasaki H; Sendo T; Ohtsuka Y; Gomita Y
    J Clin Pharm Ther; 2008 Feb; 33(1):31-8. PubMed ID: 18211614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin.
    Miles MV; Snead OC; Thorn MD
    Clin Pharm; 1988 Sep; 7(9):688-93. PubMed ID: 3149223
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum concentrations of valproic acid: influence of dose and comedication.
    May T; Rambeck B
    Ther Drug Monit; 1985; 7(4):387-90. PubMed ID: 3936236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valproate on free plasma phenytoin concentrations.
    Tsanaclis LM; Allen J; Perucca E; Routledge PA; Richens A
    Br J Clin Pharmacol; 1984 Jul; 18(1):17-20. PubMed ID: 6430316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of binding equation method for prediction of unbound serum valproic acid concentration in pediatric patients with epilepsy.
    Kodama Y; Kuranari M; Kodama H; Koike Y; Yasunaga F; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):114-8. PubMed ID: 7757310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent interaction between phenytoin and valproic acid.
    Riva R; Albani F; Contin M; Perucca E; Ambrosetto G; Gobbi G; Santucci M; Procaccianti G; Baruzzi A
    Neurology; 1985 Apr; 35(4):510-5. PubMed ID: 3920548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of total and free phenytoin serum concentrations measured by high-performance liquid chromatography and standard TDx assay: implications for the prediction of free phenytoin serum concentrations.
    May TW; Rambeck B; Jürges U; Blankenhorn V; Jürgens U
    Ther Drug Monit; 1998 Dec; 20(6):619-23. PubMed ID: 9853976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
    Ueshima S; Aiba T; Ishikawa N; Sato T; Kawasaki H; Kurosaki Y; Ohtsuka Y; Sendo T
    J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice.
    Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M
    Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate.
    de Wolff FA; Peters AC; van Kempen GM
    Neuropediatrics; 1982 Feb; 13(1):10-3. PubMed ID: 6123089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients.
    Garzón P; González-Cornejo S; Román-Maldonado S; Navarro-Ruiz A
    Gen Pharmacol; 1985; 16(4):411-3. PubMed ID: 2412936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.